| Literature DB >> 32310145 |
José Côté1,2,3, Geneviève Rouleau1,3, Maria Pilar Ramirez-Garcia1,2, Patricia Auger1,3, Réjean Thomas4, Judith Leblanc1,3,5.
Abstract
BACKGROUND: Taking antiretroviral therapy (ART) is part of the daily life of people living with HIV. Different electronic health (eHealth) initiatives adjunctive to usual care have been proposed to support optimal medication adherence. A web-based intervention called HIV Treatment, Virtual Nursing Assistance, and Education or VIH-TAVIE (from its French version Virus de l'immunodéficience humaine-Traitement assistance virtuelle infirmière et enseignement) was developed to empower people living with HIV to manage their ART and symptoms optimally.Entities:
Keywords: antiretroviral therapy; medication adherence; nursing; people living with HIV; self-management; web-based intervention; web-based randomized controlled trial
Mesh:
Year: 2020 PMID: 32310145 PMCID: PMC7199130 DOI: 10.2196/17733
Source DB: PubMed Journal: JMIR Public Health Surveill ISSN: 2369-2960
Figure 1Flow diagram. The measurement time points are baseline (T0) and 3 months (T3) and 6 months later (T6).
Baseline sociodemographic and clinical characteristics of the participants.
| Characteristic | Experimental group (N=45), n (%) or median (IQR) | Control group (N=43), n (%) or median (IQR) | |||
| Age, years | 43 (33-53) | 40 (32-50) | |||
| Male gendera | 41 (91) | 32 (78) | |||
|
| 38 (86) | 32 (84) | |||
|
| Yes | 38 (86) | 32 (84) | ||
|
| No | 6 (14) | 6 (16) | ||
|
|
|
| |||
|
| Single | 28 (65) | 26 (68) | ||
|
| In a relationship | 15 (35) | 12 (32) | ||
|
|
|
| |||
|
| Heterosexual | 8 (18) | 9 (24) | ||
|
| Homosexual | 35 (80) | 28 (74) | ||
|
| Bisexual | 1 (2) | 1 (3) | ||
| With childrenb | 6 (14) | 5 (13) | |||
| HIV-infected children | 0 (0) | 0 (0) | |||
|
|
|
| |||
|
| Primary | 0 (0) | 0 (0) | ||
|
| Secondary | 9 (21) | 13 (34) | ||
|
| College | 11 (25) | 14 (37) | ||
|
| University | 24 (55) | 11 (29) | ||
|
|
|
| |||
|
| <14,999 | 11 (26) | 11 (30) | ||
|
| 15,000-34,999 | 10 (24) | 12 (33) | ||
|
| 35,000-54,999 | 11 (26) | 8 (22) | ||
|
| >55,000 | 10 (24) | 6 (16) | ||
|
|
|
| |||
|
| Employed | 27 (64) | 17 (47) | ||
|
| Student | 1 (2) | 4 (11) | ||
|
| On welfare | 8 (19) | 5 (14) | ||
|
| Others | 6 (14) | 10 (28) | ||
|
|
|
| |||
|
| Living alone | 22 (51) | 21 (55) | ||
|
| Living with spouse | 12 (28) | 9 (24) | ||
|
| Living with family or friend | 3 (7) | 4 (11) | ||
|
| Others | 6 (14) | 4 (11) | ||
| Self-perceived health (0-10)e | 8 (7-8) | 8 (7-9) | |||
| Years of HIV infectionf | 7 (3-18) | 8 (3-16) | |||
| Years of antiretroviral therapyf | 5 (1-16) | 6 (2-10) | |||
| Undetectable viral loadg | 41 (95) | 34 (92) | |||
|
|
|
| |||
|
| Did not know | 8 (21) | 7 (18) | ||
|
| Knew | 30 (79) | 33 (83) | ||
| Value of CD4 cell count (cells/μl)h | 555 (410-690) | 650 (480-800) | |||
|
|
|
| |||
|
| Increasing | 8 (19) | 11 (30) | ||
|
| Decreasing | 7 (16) | 3 (8) | ||
|
| Stable | 16 (37) | 18 (49) | ||
|
| Did not know | 12 (28) | 5 (14) | ||
| Months since last blood controli | 1 (1-3) | 2 (0-3) | |||
| Treatment change in the past 3 monthsc | 2 (5) | 4 (11) | |||
|
|
|
| |||
|
| To switch to more effective drugs | 1 (50) | 3 (75) | ||
|
| To reduce adverse events | 2 (100) | 2 (50) | ||
|
| To simplify treatment | 0 (0) | 3 (75) | ||
|
| Others | 1 (50) | 0 (0) | ||
aTotal 86 participants (two missing).
bTotal 82 participants (six missing).
cTotal 81 participants (seven missing).
dTotal 79 participants (nine missing).
eTotal 78 participants (10 missing).
fTotal 87 participants (one missing).
gTotal 80 participants (eight missing).
hTotal 61 participants (two missing).
iTotal 85 participants (three missing).
jMore than one reason possible.
Proportion of antiretroviral-adherent participants.
| Time point | Experimental group | Control group | |||||||||
|
| Total, n | Value, n (%) | Total, n | Value, n (%) |
| ||||||
|
|
|
|
|
|
| ||||||
|
| Per-protocol analysis | 41 | 34 (83) | 39 | 30 (77) |
| |||||
|
| Intention-to-treat analysis | 45 | 34 (76) | 43 | 30 (70) |
| |||||
|
|
|
|
|
|
| ||||||
|
| Per-protocol analysis | 19 | 17 (90) | 25 | 22 (88) |
| |||||
|
| Intention-to-treat analysis | 45 | 17 (38) | 43 | 22 (51) |
| |||||
|
|
|
|
|
|
| ||||||
|
| Per-protocol analysisa | 21 | 19 (91) | 23 | 19 (83) | .67 | |||||
|
| Intention-to-treat analysisa | 45 | 19 (42) | 43 | 19 (44) | .85 | |||||
aFor the primary outcome, groups were compared using the Pearson chi-square test.
Figure 2Adherence over time. The solid bars represent the estimated proportion of treatment-adherent participants, and the error bars (lines) indicate the corresponding 95% CIs from the generalized linear mixed model. The measurement time points are baseline (T0) and 3 months (T3) and 6 months later (T6).
Secondary outcomes at 6 months (T6).
| Variable | Experimental group (N=45), median (IQR) score | Control group (N=43), median (IQR) score | |
| Symptom countb | 9.0 (6.0-14.0) | 7.5 (5.0-17.5) | .68 |
| Symptom botherc | 17.0 (11.0-29.0) | 18.5 (8.5-47.0) | .70 |
| Self-efficacyd | 67.5 (60.5-70.0) | 66.0 (62.0-69.0) | .81 |
| Social supporte | 32.0 (28.0-39.0) | 32.0 (27.0-38.0) | .83 |
| Skills and strategiesf | 97.0 (82.0-118.0) | 98.0 (90.0-111.0) | .90 |
aGroups were compared using the Student t test or Fisher exact test.
bTotal 45 participants (three missing). Possible score range 0-25.
cTotal 45 participants (three missing). Possible score range 1-100.
dTotal 39 participants (nine missing). Possible score range 14-90.
eTotal 47 participants (one missing). Possible score range 8-40.
fTotal 46 participants (two missing). Possible score range 25-125.